Big pharma, Drug delivery, Partnering, Pharma

Janssen and Ichor Medical enter hep B vaccine delivery alliance

Posted on 14 April 2015

Tags: , , ,

Ichor Medical Systems has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals.

Under the agreement, which was facilitated by Johnson & Johnson Innovation, the parties will work together to develop and commercialize DNA-based vaccine products for the treatment of chronic hepatitis B using Ichor’s TriGrid electroporation technology for clinical administration.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


Ichor will receive an upfront payment, R&D support, and development and sales milestone payments up to a potential total of approximately $85 million USD, as well as royalty payments on any future licensed product sales.

Janssen will assume responsibility for certain development costs and all commercialization costs associated with the program, including manufacturing and distribution expense for Ichor’s TriGrid Delivery System.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply